Next generation sequencing in lung cancer: An initial experience from India

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer., 136, E359, 10.1002/ijc.29210 Tsoulos, 2017, Tumor molecular profiling of NSCLC patients using next generation sequencing, Oncol. Rep., 38, 3419 Next-generation sequencing: advantages, disadvantages, and future | SpringerLink, (n.d.). https://link.springer.com/chapter/10.1007/978-3-319-31703-8_5. Chougule, 2013, Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity, PloS One, 8, e76164, 10.1371/journal.pone.0076164 Prabhash, 2017, Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test, Asian J. Oncol, 03, 039, 10.4103/ASJO.ASJO_104_16 Das, 2015, Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients, Pathol. Oncol. Res. POR., 21, 675, 10.1007/s12253-014-9874-7 Veldore, 2013, Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India, Indian J. Cancer, 50, 87, 10.4103/0019-509X.117013 Somatic STK11 and Concomitant STK11/KRAS Mutational Frequency in Stage IV Lung Adenocarcinoma Adrenal Metastases - J Thorac Oncol. 2015;10(3):531-514. doi:10.1097/JTO.0000000000000391. Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. - PubMed - NCBI, (n.d.).https://www.ncbi.nlm.nih.gov/pubmed/25695224 (Accessed November 19, 2019). 2014, Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385 Validation and application of a custom-designed targeted next-generation sequencing panel for the diagnostic mutational profiling of solid tumors, (n.d.). https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154038 (Accessed 19 November 2019). Mehrad, 2018, Next-generation sequencing approach to non-small cell lung carcinoma yields more actionable alterations, Arch. Pathol. Lab. Med., 142, 353, 10.5858/arpa.2017-0046-OA DiBardino, 2017, Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology, CytoJournal, 14, 7, 10.4103/1742-6413.202602 Deben, 2016, TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value, Crit. Rev. Oncol. Hematol., 99, 63, 10.1016/j.critrevonc.2015.11.019 Cai, 2014, Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing, PloS One, 9, e95228, 10.1371/journal.pone.0095228 Shajani-Yi, 2018, Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing, Neoplasia N. Y. N., 20, 256, 10.1016/j.neo.2017.12.005 Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts, (n.d.). Mutational Activation of the K-ras Oncogene | NEJM, (n.d.). https://www.nejm.org/doi/full/10.1056/NEJM198710083171504?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed (Accessed 4 March 2019). Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non–small cell lung cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 19 Li, 2014, Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts, Br. J. Cancer, 110, 2812, 10.1038/bjc.2014.210 Rodenhuis, 1987, Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung, N. Engl. J. Med., 317, 929, 10.1056/NEJM198710083171504 Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 19, 4273, 10.1158/1078-0432.CCR-13-0318 Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline Fro... - PubMed - NCBI, (n.d.). https://www.ncbi.nlm.nih.gov/pubmed/29355391 (Accessed 19 November 2019). Facchinetti, 2017, LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value, Lung Cancer Amst. Neth., 112, 62, 10.1016/j.lungcan.2017.08.002 Chuang, 2017, ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer., 12, 833 Arcila, 2012, Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 18, 4910, 10.1158/1078-0432.CCR-12-0912 Baik, 2017, Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy, The Oncologist, 22, 786, 10.1634/theoncologist.2016-0458 Barlesi, 2016, Biomarkers France contributors, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet Lond. Engl., 387, 1415, 10.1016/S0140-6736(16)00004-0 Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing, (n.d.). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489668/ (Accessed 19 November 2019). The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. - PubMed - NCBI, (n.d.). https://www.ncbi.nlm.nih.gov/pubmed/27734950 (Accessed 19 November 2019). Chen, 2015, Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis, Cancer Biol. Med., 12, 126 2014, Nature, 511, 543, 10.1038/nature13385 D'Haene, 2015, Clinical validation of targeted next generation sequencing for colon and lung cancers, PLoS ONE, 10 DiBardino, 2017, Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology, CytoJournal, 14, 7, 10.4103/1742-6413.202602